Citadel Advisors’s CytoMed Therapeutics GDTC Stock Holding History

Citadel Advisors’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,669	Closed	-$58.9K	–	13250
2025 Q2	$58.9K	Buy	27,669 +10,419	+60%	+$23.7K	﹤0.01%	11690
2025 Q1	$38.8K	Buy	+17,250	New	+$45.7K	﹤0.01%	12569

Other funds holding GDTC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors's GDTC Position: Q3 2025 in Review

Citadel Advisors sold out of CytoMed Therapeutics (GDTC) in Q3 2025, closing a stake of 27,669 shares — an estimated $58.9K sold.

Citadel Advisors first reported a position in GDTC in Q1 2025 and held it in 2 quarters. The position peaked at $58.9K in Q2 2025. 2 funds tracked by Wall St. Rank hold GDTC as of Q3 2025.

Citadel Advisors reported no remaining CytoMed Therapeutics position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 27,669 CytoMed Therapeutics shares in Q3 2025, an estimated $58.9K.
Citadel Advisors first reported a position in CytoMed Therapeutics in Q1 2025 and held it in 2 quarters.
Citadel Advisors's CytoMed Therapeutics position peaked at $58.9K in Q2 2025.
2 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.